Bioventus Inc (BVS)
11.12
-0.04
(-0.31%)
USD |
NASDAQ |
Nov 14, 16:00
11.12
0.00 (0.00%)
After-Hours: 20:00
Bioventus Research and Development Expense (Quarterly): 3.808M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 3.808M |
| June 30, 2024 | 3.988M |
| March 31, 2024 | 2.597M |
| December 31, 2023 | 3.262M |
| September 30, 2023 | 3.015M |
| June 30, 2023 | 3.398M |
| March 31, 2023 | 3.771M |
| December 31, 2022 | 5.946M |
| September 30, 2022 | 4.614M |
| June 30, 2022 | 6.366M |
| March 31, 2022 | 6.928M |
| Date | Value |
|---|---|
| December 31, 2021 | 7.103M |
| September 30, 2021 | 6.153M |
| June 30, 2021 | 4.836M |
| March 31, 2021 | 0.947M |
| December 31, 2020 | 2.891M |
| September 30, 2020 | 3.569M |
| June 30, 2020 | 2.596M |
| March 31, 2020 | 2.146M |
| December 31, 2019 | 3.144M |
| March 31, 2016 | 3.718M |
| March 31, 2015 | 2.966M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.947M
Minimum
Mar 2021
7.103M
Maximum
Dec 2021
4.054M
Average
3.67M
Median
Research and Development Expense (Quarterly) Benchmarks
| Boston Scientific Corp | 407.00M |
| Insulet Corp | 54.90M |
| Perspective Therapeutics Inc | 9.275M |
| Xtant Medical Holdings Inc | 0.636M |
| Catheter Precision Inc | 0.081M |